Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI
The Brown University Psychopharmacology Update · 2026-12 · 37 (12) · 1-5
DOI: 10.1002/pu.31517 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.11.2026.
Abstract (Originalsprache)
The mortality gap for people with bipolar disorder, major depressive disorder, and schizophrenia is mainly due to cardiovascular disease. Individuals with serious mental illness (SMI) have a life expectancy of 10 to 25 years shorter than the general population. This is partly due to psychopharmacotherapy‐related metabolic effects and systemic disparities in prevention and treatment, leading to the need to find interventions that address cardiovascular outcomes and metabolic risk.
Zitieren
APA
(2026). Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI. The Brown University Psychopharmacology Update, 37(12), 1-5. https://doi.org/10.1002/pu.31517
Vancouver
Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI. The Brown University Psychopharmacology Update. 2026;37(12):1-5. doi:10.1002/pu.31517
BibTeX
@article{euvimed2026,
title = {Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {12},
pages = {1--5},
doi = {10.1002/pu.31517}
}
EUVIMED